A Phase 3 interventional study of B/F/TAF and NRTIs in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 82 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-05.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the efficacy of switching from a regimen of 2 nucleos(t)Ide reverse transcriptase inhibitors (NRTIs) and a third agent to a fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing their baseline regimen in HIV-1 infected, virologically suppressed African American participants.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.
Drug: B/F/TAF
Participants will stay on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks with a delayed switch to B/F/TAF (50/200/25 mg) FDC tablet administered orally, once daily until Week 48 without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.
Drug: B/F/TAF · Drug: NRTIs · Drug: Third Agent
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
50/200/25 mg FDC tablets administered orally once daily without regard to food
Also known as: Biktarvy®
The following NRTIs will be administered as prescribed until Week 24 without regard to food: abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), zidovudine (ZDV or AZT)
Any one of the following third agents will be administered as prescribed. Protease inhibitors and EVG will be administered with the appropriate pharmacologic booster cobicistat or ritonavir. : * Non-nucleoside reverse transcriptase inhibitors (NNRTIs) * delavirdine (DLV) * efavirenz (EFV) * nevirapine (NVP) * rilpivirine (RPV) * doravirine (DOR) * Integrase inhibitors * dolutegravir (DTG) * elvitegravir (EVG) * raltegravir (RAL) * Protease inhibitors (PIs) * atazanavir (ATV) * darunavir (DRV) * lopinavir (LPV) * nelfinavir NFV) * saquinavir (SQV) * tipranavir (TPV) * Chemokine co-recptor 5 (CCR5) antagonist --maraviroc (MVC)
Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set
The percentage of participants who had HIV-1 RNA ≥ 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set
The percentage of participants who had HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.
Time frame: Week 48
Percentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set
The percentage of participants who had HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Percentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Week 24 Per Protocol Analysis Set
The percentage of participants who had HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Percentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set
The percentage of participants who had HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.
Time frame: Week 48
Change From Baseline in CD4+ Cell Count at Week 24: Full Analysis Set
The analysis includes values up to 1 day after permanent discontinuation of study treatment.
Time frame: Baseline to Week 24
Change From Baseline in CD4+ Cell Count at Week 24: Week 24 Per Protocol Analysis Set
The analysis includes values up to 1 day after permanent discontinuation of study treatment.
Time frame: Baseline to Week 24
Change From Baseline in CD4+ Cell Count at Week 48: Full Analysis Set
The analysis includes values up to 1 day after permanent discontinuation of study treatment. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.
Time frame: Baseline to Week 48
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A treatment-emergent adverse event was defined as any adverse event with onset date on or after the study treatment start date and no later than 30 days after the study drug stop date; or any adverse event leading to study drug discontinuation.
Time frame: First B/F/TAF dose date up to Week 72 plus 30 days
Percentage of Participants Experiencing Treatment-Emergent Graded Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Severity grades were defined by 'Gilead Grading Scale for Severity of AEs and Laboratory Abnormalities'.
Time frame: First B/F/TAF dose date up to Week 72 plus 30 days
Participants were enrolled at study centers in the United States. The first participant was screened on 28 August 2018. The last study visit occurred on 19 August 2020.
| Milestone | B/F/TAF | Stay on Baseline Regimen (SBR)/ Delayed B/F/TAF |
|---|---|---|
| Started | 331 | 165 |
| Completed | 324 | 163 |
| Not completed | 7 | 2 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Withdrew consent | 1 | 2 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Randomized but not treated | 1 | 0 |
| Milestone | B/F/TAF | Stay on Baseline Regimen (SBR)/ Delayed B/F/TAF |
|---|---|---|
| Started | 319 | 163 |
| Completed | 303 | 158 |
| Not completed | 16 | 5 |
| Withdrew: Lost to follow-up | 6 | 1 |
| Withdrew: Withdrew consent | 3 | 3 |
| Withdrew: Adverse event | 4 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Investigator's discretion | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
The percentage of participants who had HIV-1 RNA ≥ 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF | Stay on Baseline Regimen (SBR) |
|---|---|---|
| Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set | 0.6 (0.1 to 2.2) | 1.8 (0.4 to 5.2) |
The percentage of participants who had HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.
| percentage of participants | B/F/TAF | Delayed B/F/TAF |
|---|---|---|
| Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set | 0.9 (0.2 to 2.6) | 0 (0.0 to 2.2) |
The percentage of participants who had HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF | Stay on Baseline Regimen (SBR) |
|---|---|---|
| Percentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set | 96.3 (93.7 to 98.1) | 94.5 (89.9 to 97.5) |
The percentage of participants who had HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF | Stay on Baseline Regimen (SBR) |
|---|---|---|
| Percentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Week 24 Per Protocol Analysis Set | 99.3 (97.7 to 99.9) | 98.0 (94.2 to 99.6) |
The percentage of participants who had HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.
| percentage of participants | B/F/TAF | Delayed B/F/TAF |
|---|---|---|
| Percentage of Participants Who Had HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set | 94.5 (91.5 to 96.7) | 96.9 (93.0 to 99.0) |
The analysis includes values up to 1 day after permanent discontinuation of study treatment.
| cells/uL | B/F/TAF | Stay on Baseline Regimen (SBR) |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 24: Full Analysis Set | 13 ± 209.3 | 1 ± 171.2 |
The analysis includes values up to 1 day after permanent discontinuation of study treatment.
| cells/uL | B/F/TAF | Stay on Baseline Regimen (SBR) |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 24: Week 24 Per Protocol Analysis Set | 13 ± 210.1 | 4 ± 171.3 |
The analysis includes values up to 1 day after permanent discontinuation of study treatment. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.
| cells/uL | B/F/TAF | Delayed B/F/TAF |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 48: Full Analysis Set | 7 ± 188.6 | -8 ± 159.2 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A treatment-emergent adverse event was defined as any adverse event with onset date on or after the study treatment start date and no later than 30 days after the study drug stop date; or any adverse event leading to study drug discontinuation.
| percentage of participants | B/F/TAF | Delayed B/F/TAF |
|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 83.3 | 69.3 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Severity grades were defined by 'Gilead Grading Scale for Severity of AEs and Laboratory Abnormalities'.
| percentage of participants | B/F/TAF | Delayed B/F/TAF |
|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Graded Laboratory Abnormalities | 87.8 | 80.4 |
Collected over Adverse Events: First B/F/TAF dose date up to Week 72 plus 30 days. All-Cause Mortality: Randomization up to Week 72 plus 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B/F/TAF up to Week 24 | 1/331 (0.3%) | 13/330 (3.9%) | 38/330 (11.5%) |
| SBR up to Week 24 | 0/165 (0%) | 7/165 (4.2%) | 13/165 (7.9%) |
| B/F/TAF After Week 24 | 2/319 (0.6%) | 20/319 (6.3%) | 53/319 (16.6%) |
| Delayed B/F/TAF | 0/163 (0%) | 7/163 (4.3%) | 26/163 (16%) |
| Event | B/F/TAF up to Week 24 | SBR up to Week 24 | B/F/TAF After Week 24 | Delayed B/F/TAF |
|---|---|---|---|---|
| Covid-19Infections and infestations | 0/330 | 0/165 | 3/319 | 0/163 |
| Chest painGeneral disorders | 0/330 | 0/165 | 2/319 | 0/163 |
| Acute myocardial infarctionCardiac disorders | 0/330 | 0/165 | 1/319 | 1/163 |
| Gastric stenosisGastrointestinal disorders | 0/330 | 0/165 | 0/319 | 1/163 |
| Complication associated with deviceGeneral disorders | 0/330 | 0/165 | 0/319 | 1/163 |
| CellulitisInfections and infestations | 0/330 | 0/165 | 0/319 | 1/163 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/330 | 0/165 | 0/319 | 1/163 |
| Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/330 | 0/165 | 0/319 | 1/163 |
| Lacunar infarctionNervous system disorders | 0/330 | 0/165 | 0/319 | 1/163 |
| Bipolar I disorderPsychiatric disorders | 0/330 | 0/165 | 0/319 | 1/163 |
| Event | B/F/TAF up to Week 24 | SBR up to Week 24 | B/F/TAF After Week 24 | Delayed B/F/TAF |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 20/330 | 6/165 | 17/319 | 10/163 |
| SyphilisInfections and infestations | 4/330 | 1/165 | 18/319 | 7/163 |
| DiarrhoeaGastrointestinal disorders | 11/330 | 5/165 | 4/319 | 9/163 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 5/330 | 2/165 | 16/319 | 6/163 |
The Safety Analysis Set included all participants who were randomized into the study and had received at least 1 dose of study treatment (either B/F/TAF or baseline regimen on Day 1).
| Age, Continuous(years) | B/F/TAF | Stay on Baseline Regimen/ Delayed B/F/TAF | Total |
|---|---|---|---|
| Mean | 47 ± 12.3 | 48 ± 12.2 | 47 ± 12.2 |
| Sex: Female, Male(Participants) | B/F/TAF | Stay on Baseline Regimen/ Delayed B/F/TAF | Total |
|---|---|---|---|
| Female | 101 | 55 | 156 |
| Male | 229 | 110 | 339 |
| Ethnicity (NIH/OMB)(Participants) | B/F/TAF | Stay on Baseline Regimen/ Delayed B/F/TAF | Total |
|---|---|---|---|
| Hispanic or Latino | 15 | 5 | 20 |
| Not Hispanic or Latino | 315 | 160 | 475 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | B/F/TAF | Stay on Baseline Regimen/ Delayed B/F/TAF | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Black or African American | 285 | 154 | 439 |
| Native Hawaiian or Pacific Islander | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| Other | 45 | 11 | 56 |
| HIV-1 RNA Category(Participants) | B/F/TAF | Stay on Baseline Regimen/ Delayed B/F/TAF | Total |
|---|---|---|---|
| < 50 copies/mL | 325 | 163 | 488 |
| ≥ 50 copies/mL | 5 | 2 | 7 |
| CD4+ Cell Count(cells/µL) | B/F/TAF | Stay on Baseline Regimen/ Delayed B/F/TAF | Total |
|---|---|---|---|
| Mean | 765 ± 313.4 | 757 ± 323.0 | 763 ± 316.3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Aug 2018 to primary completion in Aug 2019, 11 months.
Results were first posted in Aug 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide